31 Aug 2018 Update on TULIP 1 Phase III trial for anifrolumab in systemic lupus erythematosus
30 Aug 2018 Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies for the Treatment of Duchenne Muscular Dystrophy
29 Aug 2018 European Commission Approves BLINCYTO® (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
29 Aug 2018 Celltrion Finalizes Clinical Trials for Remsima SC, Planning to File a Marketing Authorization Application to the EMA in H2
29 Aug 2018 Biogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
29 Aug 2018 Theratechnologies Files Marketing Authorization Application for Trogarzo™ in Europe
26 Aug 2018 Shire Announces FDA Approval of TAKHZYRO™ (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary Angioedema
24 Aug 2018 U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
22 Aug 2018 OSE Immunotherapeutics Publishes New Efficacy Data on FR104, CD28-Antagonist Immunotherapy
22 Aug 2018 argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody
21 Aug 2018 ProMIS Neurosciences Oligomer Selective Antibody Therapeutic for Alzheimer's Disease, PMN310, Shows Potential for Improved Safety Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies in Clinical Development
21 Aug 2018 Viela Bio Announces Start of First Clinical Trial
21 Aug 2018 Bio-Thera Solutions Announces China National Drug Administration Acceptance of Biologics License Application for Proposed Biosimilar to Humira® (Adalimumab)
21 Aug 2018 FDA Approves Expanded Label for Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed (ALIMTA®) and Platinum Chemotherapy for First-Line Treatment of Patients with Metastatic Nonsquamous NSCLC, with No EGFR or ALK Genomic Tumor Aberrations
20 Aug 2018 FDA Accepts Priority Review of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the US
20 Aug 2018 Development partner Boehringer Ingelheim supplies clinical material manufactured in China for new cancer drug
20 Aug 2018 Immunocore Announces Start of Phase I ImmTAC® Study in Patients with Solid Tumours
18 Aug 2018 FDA Approves EYLEA® (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration
17 Aug 2018 U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as the First New Medication in Nearly 20 Years for Certain Patients with Previously Treated Small Cell Lung Cancer
16 Aug 2018 Regeneron and Teva Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip
16 Aug 2018 Ebola successfully neutralized by latest generation polyclonal immunotherapy
13 Aug 2018 Regeneron Provides Regulatory Update on EYLEA® (aflibercept) Injection sBLA in Wet Age-Related Macular Degeneration
13 Aug 2018 Stemline Therapeutics Announces that FDA Accepts ELZONRIS™ Biologics License Application (BLA) and Grants Priority Review
13 Aug 2018 FDA Grants Breakthrough Therapy Designation for Xolair (Omalizumab) for Food Allergies
13 Aug 2018 Samsung Bioepis to Initiate Phase 1 Clinical Trial of SB26 Ulinastatin-Fc Fusion Protein

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up